403 related articles for article (PubMed ID: 23507481)
1. Role of DNA methylation in the pathogenesis and treatment of myelodysplastic syndromes.
Khan H; Vale C; Bhagat T; Verma A
Semin Hematol; 2013 Jan; 50(1):16-37. PubMed ID: 23507481
[TBL] [Abstract][Full Text] [Related]
2. [Epigenetic therapy in myelodysplastic syndromes (MDS). Treatment with DNA methyltransferase inhibitors].
Daskalakis M; Blagitko-Dorfs N; Hackanson B; Lübbert M
Pharm Unserer Zeit; 2010 May; 39(3):217-27. PubMed ID: 20425776
[No Abstract] [Full Text] [Related]
3. DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias.
Leone G; Teofili L; Voso MT; Lübbert M
Haematologica; 2002 Dec; 87(12):1324-41. PubMed ID: 12495905
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic regulation in myelodysplastic syndromes: implications for therapy.
Vigna E; Recchia AG; Madeo A; Gentile M; Bossio S; Mazzone C; Lucia E; Morabito L; Gigliotti V; Stefano LD; Caruso N; Servillo P; Franzese S; Fimognari F; Bisconte MG; Gentile C; Morabito F
Expert Opin Investig Drugs; 2011 Apr; 20(4):465-93. PubMed ID: 21381982
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic therapy in myelodysplastic syndromes.
Musolino C; Sant'antonio E; Penna G; Alonci A; Russo S; Granata A; Allegra A
Eur J Haematol; 2010 Jun; 84(6):463-73. PubMed ID: 20192987
[TBL] [Abstract][Full Text] [Related]
6. Combination therapy with DNA methyltransferase inhibitors in hematologic malignancies.
Gore SD
Nat Clin Pract Oncol; 2005 Dec; 2 Suppl 1():S30-5. PubMed ID: 16341238
[TBL] [Abstract][Full Text] [Related]
7. Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia.
Estey EH
Leukemia; 2013 Sep; 27(9):1803-12. PubMed ID: 23757301
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic changes in therapy-related MDS/AML.
Voso MT; D'Alò F; Greco M; Fabiani E; Criscuolo M; Migliara G; Pagano L; Fianchi L; Guidi F; Hohaus S; Leone G
Chem Biol Interact; 2010 Mar; 184(1-2):46-9. PubMed ID: 19874806
[TBL] [Abstract][Full Text] [Related]
9. DNA methyltransferases in hematologic malignancies.
Li KK; Luo LF; Shen Y; Xu J; Chen Z; Chen SJ
Semin Hematol; 2013 Jan; 50(1):48-60. PubMed ID: 23507483
[TBL] [Abstract][Full Text] [Related]
10. DNA methyltransferase inhibitors in cancer: a chemical and therapeutic patent overview and selected clinical studies.
Fahy J; Jeltsch A; Arimondo PB
Expert Opin Ther Pat; 2012 Dec; 22(12):1427-42. PubMed ID: 23033952
[TBL] [Abstract][Full Text] [Related]
11. Genome-wide profiling of methylation identifies novel targets with aberrant hypermethylation and reduced expression in low-risk myelodysplastic syndromes.
del Rey M; O'Hagan K; Dellett M; Aibar S; Colyer HA; Alonso ME; Díez-Campelo M; Armstrong RN; Sharpe DJ; Gutiérrez NC; García JL; De Las Rivas J; Mills KI; Hernández-Rivas JM
Leukemia; 2013 Mar; 27(3):610-8. PubMed ID: 22936014
[TBL] [Abstract][Full Text] [Related]
12. Current status of epigenetic treatment in myelodysplastic syndromes.
Kuendgen A; Lübbert M
Ann Hematol; 2008 Aug; 87(8):601-11. PubMed ID: 18392623
[TBL] [Abstract][Full Text] [Related]
13. Aberrant promotor methylation in MDS hematopoietic cells during in vitro lineage specific differentiation is differently associated with DNMT isoforms.
Hopfer O; Komor M; Koehler IS; Freitag C; Schulze M; Hoelzer D; Thiel E; Hofmann WK
Leuk Res; 2009 Mar; 33(3):434-42. PubMed ID: 18829110
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic therapies in MDS and AML.
Griffiths EA; Gore SD
Adv Exp Med Biol; 2013; 754():253-83. PubMed ID: 22956506
[TBL] [Abstract][Full Text] [Related]
15. In vivo effects of decitabine in myelodysplasia and acute myeloid leukemia: review of cytogenetic and molecular studies.
Hackanson B; Robbel C; Wijermans P; Lübbert M
Ann Hematol; 2005 Dec; 84 Suppl 1():32-8. PubMed ID: 16292549
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of the EZH2, RING1 and BMI1 genes is common in myelodysplastic syndromes: relation to adverse epigenetic alteration and poor prognostic scoring.
Xu F; Li X; Wu L; Zhang Q; Yang R; Yang Y; Zhang Z; He Q; Chang C
Ann Hematol; 2011 Jun; 90(6):643-53. PubMed ID: 21125401
[TBL] [Abstract][Full Text] [Related]
18. [Application of DNA methyltransferase inhibitors for myelodysplastic syndrome].
Lü XY; Du YX; Dai ZH; Liu M; Liu XY; Zhang KL
Yi Chuan; 2013 Feb; 35(2):136-40. PubMed ID: 23448925
[TBL] [Abstract][Full Text] [Related]
19. Clinical results with the DNA hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in patients with myelodysplastic syndromes: an update.
Joeckel TE; Lübbert M
Semin Hematol; 2012 Oct; 49(4):330-41. PubMed ID: 23079063
[TBL] [Abstract][Full Text] [Related]
20. DNA methylation changes following 5-azacitidine treatment in patients with myelodysplastic syndrome.
Tran HT; Kim HN; Lee IK; Kim YK; Ahn JS; Yang DH; Lee JJ; Kim HJ
J Korean Med Sci; 2011 Feb; 26(2):207-13. PubMed ID: 21286011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
